Skip to content
Enalapril
Epaned, Lexxel, Teczem, Vaseretic, Vasotec (enalapril) is a small molecule pharmaceutical. Enalapril was first approved as Vasotec on 1985-12-24. It is used to treat bartter syndrome, diabetic nephropathies, edema, heart failure, and left ventricular dysfunction amongst others in the USA. The pharmaceutical is active against angiotensin-converting enzyme.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
urogenital diseasesD000091642
cardiovascular diseasesD002318
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Epaned, Vasotec (generic drugs available since 2000-08-22)
Combinations
Vaseretic (generic drugs available since 2000-08-22, discontinued: Lexxel, Teczem)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Diltiazem malate
+
Enalapril maleate
Tradename
Company
Number
Date
Products
TECZEMBausch Health CompaniesN-020507 DISCN1996-10-04
1 products
Hide discontinued
Enalapril maleate
Tradename
Company
Number
Date
Products
EPANEDAzurityN-208686 RX2016-09-20
1 products, RLD, RS
VASOTECBausch Health CompaniesN-018998 RX1985-12-24
4 products, RLD, RS
Show 1 discontinued
Enalapril maleate
+
Felodipine
Tradename
Company
Number
Date
Products
LEXXELAstraZenecaN-020668 DISCN1996-12-27
2 products
Hide discontinued
Enalapril maleate
+
Hydrochlorothiazide
Tradename
Company
Number
Date
Products
VASERETICBausch Health CompaniesN-019221 RX1986-10-31
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
enalapril maleateANDA2023-06-15
epanedNew Drug Application2020-03-31
vasereticNew Drug Application2020-08-31
vasotecNew Drug Application2020-12-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
bartter syndromeOrphanet_112D001477E26.81
diabetic nephropathiesEFO_0000401D003928
edemaD004487R60.9
heart failureEFO_0003144D006333I50
left ventricular dysfunctionD018487
malignant hypertensionEFO_1001031D006974
rheumatoid arthritisEFO_0000685D001172M06.9
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Enalapril Maleate, Epaned, Azurity
96690082036-03-25DP
98084422036-03-25U-3, U-71, U-185, U-1723, U-1892
100397452036-03-25DP
101549872036-03-25U-3, U-71, U-185, U-1723, U-1892
107728682036-03-25DP
107864822036-03-25DP
110400232036-03-25DP
111414052036-03-25DP
111731412036-03-25DP
Enalapril Maleate, Epaned Kit, Silvergate Pharms
85687472032-11-06DP
87783662032-11-06U-3, U-71, U-185, U-1723, U-1892
98552142032-11-06DP
99685532032-11-06U-3, U-71, U-185, U-1723, U-1892
ATC Codes
C: Cardiovascular system drugs
C09: Agents acting on the renin-angiotensin system
C09A: Ace inhibitors, plain
C09AA: Ace inhibitors, plain
C09AA02: Enalapril
C09B: Ace inhibitors, combinations
C09BA: Ace inhibitors and diuretics
C09BA02: Enalapril and diuretics
C09BB: Ace inhibitors and calcium channel blockers
C09BB02: Enalapril and lercanidipine
C09BB06: Enalapril and nitrendipine
HCPCS
No data
Clinical
Clinical Trials
113 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart failureD006333EFO_0003144I50141510128
HypertensionD006973EFO_0000537I1025118327
Cardiovascular diseasesD002318EFO_0000319I982226
Type 2 diabetes mellitusD003924EFO_0001360E111113
Essential hypertensionD000075222I101213
AtherosclerosisD050197EFO_0003914I25.1112
Iga glomerulonephritisD005922EFO_0004194112
Pre-eclampsiaD011225EFO_0000668O14112
Healthy volunteers/patients112
CardiotoxicityD066126EFO_1001482112
Show 17 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Congenital heart defectsD006330HP_0001627Q24.9244
Coronary diseaseD0033271213
Heart diseasesD006331EFO_0003777I51.9123
Dilated cardiomyopathyD002311EFO_0000407I42.0233
ProteinuriaD011507HP_0000093R80112
Erectile dysfunctionD007172EFO_0004234F52.21112
Breast neoplasmsD001943EFO_0003869C50112
NeoplasmsD009369C8022
Diabetic nephropathiesD003928EFO_00004011112
Myocardial ischemiaD017202EFO_1001375I20-I25112
Show 12 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cerebral hemorrhageD002543213
StrokeD020521EFO_0000712I63.9112
Blood pressureD001794EFO_000432522
Chronic renal insufficiencyD051436N181112
Type 1 diabetes mellitusD003922EFO_0001359E1011
MelanomaD00854511
GlomerulonephritisD005921N0511
Membranoproliferative glomerulonephritisD01543211
Vascular diseasesD014652EFO_0004264I7711
Rheumatoid arthritisD001172EFO_0000685M06.911
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Barrett esophagusD001471EFO_0000280K22.711
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Lupus nephritisD008181EFO_000576111
Fabry diseaseD000795E75.2111
PrehypertensionD05824611
ExerciseD015444EFO_000048311
Atrial fibrillationD001281EFO_0000275I48.011
Morbid obesityD009767EFO_000107411
Sickle cell anemiaD000755EFO_0000697D5711
Spinal cord injuriesD013119EFO_100191911
Orthostatic hypotensionD007024I95.111
Intracranial hemorrhagesD020300EFO_0000551I6211
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameENALAPRIL
INNenalapril
Description
Enalapril is a dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration). It has a role as a prodrug, an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor, an antihypertensive agent and a geroprotector. It is a dicarboxylic acid monoester and a dipeptide. It is functionally related to an enalaprilat (anhydrous).
Classification
Small molecule
Drug classnarcotic agonists/antagonists (normorphine type); antihypertensives (ACE inhibitors)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O
Identifiers
PDB
CAS-ID75847-73-3
RxCUI3827
ChEMBL IDCHEMBL578
ChEBI ID4784
PubChem CID5388962
DrugBankDB00584
UNII ID69PN84IO1A (ChemIDplus, GSRS)
Target
Agency Approved
ACE
ACE
Organism
Homo sapiens
Gene name
ACE
Gene synonyms
DCP, DCP1
NCBI Gene ID
Protein name
angiotensin-converting enzyme
Protein synonyms
angiotensin I converting enzyme (peptidyl-dipeptidase A) 1, carboxycathepsin, CD143, CD143 antigen, dipeptidyl carboxypeptidase 1, Dipeptidyl carboxypeptidase I, Kininase II, peptidase P
Uniprot ID
Mouse ortholog
Ace (11421)
angiotensin-converting enzyme (P09470)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 18,005 documents
View more details
Safety
Black-box Warning
Black-box warning for: Enalapril maleate, Epaned, Vaseretic, Vasotec
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,654 adverse events reported
View more details